首页找职位找猎头

Principal/Senior scientist(MedCh...

ID:125532810 分享到微信

| |

  • 五险一金
  • 员工旅游
  • 交通补贴
  • 绩效奖金
  • 年终奖金
  • 定期体检
职位信息
  • 启动日期:2020-09-19
  • 招聘部门:其他
  • 汇报对象:无
  • 下属人数:无
  • 职位描述:
  • 工作职责:

    a)Act as chemistry leader within cross-functional project teams to evaluate, prioritize and set strategy to positively influence project direction and timelines;

    b)Efficiently manage CRO resource al"location" and utilization; oversee synthetic problem solving to ensure quality and efficiency of each project;

    c)Thoughtfully analyze biological data to help decision making and to ensure timely progress of each project;

    d)Work closely with CADD and DMPK to streamline the discovery efforts;

    e)Provide regular and integrated summaries and updates to senior management teams;

    f)Actively participating in nominating new frontier targets and establishing new drug discovery programs; helping create an environment to channel scientific curiosity to build and deliver a sustainable portfolio;

    g)Advancing the Innovent Research Portfolio and presenting/publishing project results in scientific meetings, patents and peer-reviewed literature;

    任职资格:

    1.Ms. or Ph.D. degree in chemistry with 3~10 years’ experience in the pharmaceutical/biotech industry alongside a strong track record of scientific innovation in the medicinal chemistry discipline;

    2.Familiar with modern organic synthetic chemistry and purification/analytical methods;

    3.Deep understanding of both hit and lead generation, structure-based drug design and lead optimization;

    4.Innovative team-player with high energy for fast-paced environment;

    5.Experience in leading and managing early discovery projects;

    6.Extensive working knowledge of modern medicinal chemistry and synthetic chemistry;

    7.Experience managing scientific collaborations and CRO outsourcing activities;

    8.Excellent written and verbal communication skills;

职位要求
  • 年龄要求:不限

    工作年限:3-4年

  • 学历要求:硕士及以上

    专业要求:不限

  • 是否统招:统招

    语言要求:无

企业介绍

信达生物成立于2011年,致力于开发、生产和销售用于治疗肿瘤等重大疾病的创新药物。2018年10月31日,信达生物制药在香港联交所主板挂牌上市,股票代码:01801。

自成立以来,公司凭借创新成果和国际化的运营模式在众多生物制药公司中脱颖而出。建立起了一条包括23个新药品种的产品链,覆盖肿瘤、代谢疾病、自身免疫等多个疾病领域,其中6个品种入选国家“重大新药创制”专项,18个品种进入临床研究,5个品种进入临床III期或关键性临床研究,3个单抗产品上市申请被NMPA受理,其中2个被纳入优先审评,2个产品(信迪利单抗注射液,商品名:达伯舒?,英文商标:TYVYT?;贝伐珠单抗生物类似药,商品名:达攸同?,英文商标:BYVASDA?)获得NMPA批准上市。信迪利单抗已于2019年11月成功进入国家医保目录,成为***一个进入新版国家医保目录的PD-1抑制剂。

目前,公司按照NMPA、美国FDA和欧盟EMA的GMP标准建成了高端生物药产业化基地。产业化生产线已通过合作方国际制药集团对产业化生产要求的GMP审计。公司已组建了一支具有国际先进水平的高端生物药开发、产业化人才团队,其中包括100多位海归专家。公司立足自主创新的产品与美国礼来制药集团达成了两次总金额超过15亿美元的全面战略合作,创造了多个“中国***”。

“始于信,达于行”,开发出老百姓用得起的高质量生物药,是信达生物的理想和目标。

信达生物制药(苏州)有限公司

  • 外资(欧美)
  • 1000-5000人
  • 制药/医疗
  • 上海市长宁区紫云路421号 SOHO天山广场 T1-11楼 地图